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Abstract 
Transmyocardial revascularization (TMR) has emerged as an additional therapeutic option for patients suffering from 
diffuse coronary artery disease (CAD), providing immediate angina relief. Recent studies indicate that the volume of 
surgical cases being performed with TMR have been steadily rising, utilizing TMR as an adjunctive therapy. Therefore 
the purpose of this review is to provide an up-to-date appreciation of the current state of TMR and its future devel-
opmental directions on CAD treatment. The current potential of this therapy focuses on the implementation of stem 
cells, in order to create a synergistic angiogenic effect while increasing myocardial repair and regeneration. Although 
TMR procedures provide increased vascularization within the myocardium, patients suffering from ischemic cardio-
myopathy may not benefit from angiogenesis alone. Therefore, the goal of introducing stem cells is to restore the 
functional state of a failing heart by providing these cells with a favorable microenvironment that will enhance stem 
cell engraftment.
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Background
A significant number of patients currently suffering 
from coronary artery disease (CAD) experience severe 
ischemia due to multi-vessel atherosclerotic obstruction, 
leading to heart failure and impaired myocardial func-
tion (Allen et al. 2008). Prophylaxis and treatment for this 
patient population involves drug therapy, percutaneous 
coronary interventions (PCI) and coronary artery bypass 
grafting (CABG) (Allen et  al. 2008; Kim et  al. 2002). A 
large portion of these patients suffer from refractory 
CAD not amenable to percutaneous or conventional sur-
gical interventions (Andréll et al. 2011; Allen et al. 2008; 
Kim et  al. 2002). For this patient population the extent 
of CAD is widespread and traditional revascularization 
alone is not sufficient to reinstate adequate flow through 
the coronary vessels. Transmyocardial revascularization 
(TMR) has emerged as an additional therapeutic option. 
It has been reported to provide symptomatic angina relief 
with improved quality of life, decreased cardiac events 
and decreased cardiac re-hospitalizations (Allen et  al. 
1999; Gowdak et  al. 2008; Reyes et  al. 2010; Tasse and 
Arora 2007).
Within the past decade, research has encompassed the 
use of stem cells in conjunction with TMR as a novel dual 
therapeutic option (Dallan et  al. 2008; Patel et  al. 2007; 
Spiegelstein et al. 2007; Shahzad et al. 2012). Even though 
TMR procedures may provide increased vascularization 
within the myocardium, patients suffering from ischemic 
cardiomyopathy with depressed ventricular function 
may not benefit from angiogenesis alone. Therefore, 
with the introduction of stem cells the goal is to restore 
the functional status of a failing heart by enhancing stem 
cell homing and engraftment. Due to the regenerative 
capabilities of stem cells, (Tavris et  al. 2012; Samuels 
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et  al. 2004; Horvath 2008; Lindsay 2003) it is predicted 
that concomitant injection with TMR may produce a 
synergistic effect that will improve cardiac function 
by decreasing patient angina and aiding in myocardial 
recovery, repair and regeneration.
Operative technique
TMR therapy can be performed with or without adjunc-
tive CABG or other surgical procedures and it can be uti-
lized with or without cardiopulmonary bypass support. 
For stand-alone laser therapy, a left anterior thoracot-
omy is performed in the fifth intercostal space, allowing 
exposure of the pericardium and left ventricular epicar-
dial surface (Fig. 1). Typically 20–40 channels are gener-
ated within the left ventricle, depending on the ischemic 
region and size of the patient heart. Channels are first 
employed on the inferior surface, moving towards the 
apex of the heart and subsequently on the lateral and 
anterior aspects of the epicardial surface (Frazier et  al. 
2004; Tavris et al. 2012) (Fig. 2).
Considering most TMR procedures are performed 
concomitantly with CABG (Tavris et al. 2012), a median 
sternotomy and CPB support can be utilized during 
adjunctive therapy (Fig.  3). Under these conditions, 
TMR channels can be created on an arrested or beating 
heart depending on the type of laser being employed. 
The carbon dioxide laser power source is only used on 
a beating heart with ECG synchronization while the 
holmium:yttrium–aluminum–garnet (Ho:YAG) TMR 
laser can be operated on a beating or arrested heart dur-
ing bypass (Samuels et  al. 2004; Horvath 2008). If the 
surgeon performs the procedure on a beating heart after 
CPB, laser therapy can be completed following bypass 
grafting in order to create channels in areas that are not 
bypassable via grafts or that may provide inadequate 
blood supply. However if laser therapy is performed 
before bypass grafting and CPB (Frazier et al. 2004), ini-
tially bleeding can be controlled and will subside by the 
time surgery is complete (Samuels et  al. 2004). In addi-
tion, TMR therapy can be employed after the CABG pro-
cedure, while remaining on bypass with a beating heart 
(Ak et al. 2009). In this setup the patient can be placed on 
partial CPB, allowing for increased left ventricular filling 
and better tactile and auditory responses during channel 
creation. Lastly, if CPB support is used CABG and TMR 
can be performed in either order on a still heart, avoiding 
ventricular arrhythmias and controlling excessive chan-
nel bleeding (Samuels et al. 2004).
Types of laser devices
There are two main types of TMR lasers that are cur-
rently approved for surgical use, the carbon dioxide 
(CO2) and the holmium:yttrium–aluminum–garnet 
Fig. 1 Transmyocardial revascularization (TMR). TMR is performed 
on the heart by lasing channels in the myocardium, with an energy 
output of 7 W per laser pulse using the Ho:YAG fiber optic hand tool. 
The grey region seen on the heart represents an infarcted zone follow-
ing ischemic damage. Depending on the ischemic region and size of 
the patient heart, a total of 20–40 channels are created using the TMR 
laser hand piece. Typically, channels are placed on the antero-lateral, 
apical, and infero-apical regions of the heart
Fig. 2 Operative technique for stand-alone TMR therapy. Without 
CPB support a left anterior thoracotomy can be performed with a 
robotics device or manually through the fifth intercostal space. TMR is 
then performed on a beating heart
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(Ho:YAG) laser system (Allen et al. 2008; Horvath 2008). 
Both create 1 mm wide channels within the myocardium 
that traverse the ventricular wall (Deckelbaum 1994). 
The CO2 laser system uses carbon dioxide gas excitation 
to generate infrared light and ablate surrounding tissue. 
Since the CO2 laser can only be delivered to a beating 
heart, the laser should be pulsed when the heart is quies-
cent or when it is electrically minimally active, to reduce 
the risk of arrhythmias (Samuels et  al. 2004). This state 
corresponds to the time lapse between the R and T wave 
of an ECG rhythm. By avoiding laser pulsation during 
myocardial contraction, the CO2 laser prevents inter-
ruption of electrical signaling within the heart, increases 
laser accuracy and prevents laser firing to non-targeted 
areas of the myocardium, ultimately reducing the risk of 
fibrillation (Rudko and Linhares 1992). Once the laser is 
deployed in a single pulse, the lased energy is transmitted 
through the myocardial tissue and dissipated within the 
ventricular blood, preventing excessive thermal injury to 
surrounding tissue. The CO2 laser can deliver 800 W in 
one pulse lasting from 1 to 99  ms at energies of 8–80  J 
(Allen et al. 2008).
In contrast, the Ho:YAG laser system can deliver 7 W 
per pulse with five pulses being delivered per second to a 
beating or non-beating heart (Allen et al. 2008; Horvath 
2008). Unlike the CO2 laser, the Ho:YAG laser delivers 
Fig. 3 Operative technique for adjunctive TMR therapy. Surgery can be completed with or without CPB support. If CPB is used with an arrested 
heart, TMR and CABG can be performed according to surgeon preference. However if CPB is utilized with a beating heart, TMR can be performed 
prior to CPB initiation or it can be performed following bypass grafting on full or partial bypass
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solid-state holmium:YAG through a fiber optic bundle 
with pulsation. Channels are placed one centimeter apart 
and are pulsed on the anterior, lateral, and inferior walls 
of the left ventricle (Gowdak et al. 2008). Typically 10–20 
pulses are necessary to achieve successful penetration via 
tactile and auditory feedback (Samuels et al. 2004; Hor-
vath 2008).
TMR mechanisms of action and kinetics
There are 3 competing mechanisms considered to be 
the source of improved myocardial oxygenation, angina 
relief and cardiovascular function. The first mechanism 
focuses on the mechanical perturbations or channels that 
are created within the myocardium. Termed the patent 
channel theory, historically this model postulates that 
TMR creates open conduits that provide the surrounding 
ischemic myocardium with nutrients and oxygen, acting 
as sinuses that have the potential to communicate with 
neighboring cardiac capillary beds. However, this the-
ory has been received with much controversy, as studies 
show variable channel patency at various time intervals. 
Hardy et  al. (1987) reported channel patency in female 
puppies for 2 weeks using the CO2 laser as compared to 
a 48 h patency time using a simple needle puncture as a 
control. Alternatively channel patency has been observed 
in humans for at least 3 months post mortem via histo-
logical measures (Cooley et al. 1994). Although this the-
ory received support early on in TMR development, it 
has currently been rejected. Acutely, blood flow through 
lased channels stops momentarily and histology stains 
display early postoperative clot formation (Mueller et al. 
1999).
A model focusing on the denervation of the myocar-
dium has attained increased acceptance as a probable 
explanation for the short term effects noted after TMR 
therapy and for the decline in angina score following 
laser intervention. TMR is thought to disrupt the sym-
pathetic afferent nerve fibers within the myocardium, 
therefore interrupting pain signaling (Allen et  al. 2008). 
Sympathetic denervation was observed in 6 out of 8 
TMR patients with an average increase in sympathetic 
denervation of 27.5 ± 15.9 % (p = 0.03) within 2 months 
of treatment (Al-Sheikh et  al. 1999). The denervation 
hypothesis appears to be responsible for the acute effects 
of TMR, resulting in pain cessation and angina relief 
almost immediately following surgery. Cardiac nocicep-
tors and afferent fibers are located on the superficial layer 
of the myocardium, allowing for communication with the 
brain. Since these receptors are located topically they are 
easily accessible by the TMR laser. Further examination 
of the denervation theory suggests that efferent fibers 
may be denervated following laser therapy. As the active 
sites of norepinephrine production, denervating these 
areas would provide β-blockade and thus reduced ino-
tropic support, leading to decreased oxygen consumption 
and angina relief (Cardarelli 2006).
Since denervation provides a plausible explanation for 
short-term angina relief, a secondary mechanism must 
be accountable for the long-term effects associated with 
TMR. Many studies have reported increased vascular 
density post-TMR treatment suggesting that this laser 
therapy can induce angiogenesis (Fig. 4). If so, such a the-
ory could explain the increase in myocardial perfusion 
that is observed following laser therapy, especially since 
the patent channel theory is currently being debated. 
Histological samples taken from deceased patients indi-
cated the presence of necrotic tissue and inflammation 
at days 3 and 16. However, at day 150 fibrous scarring 
and increased capillary networks were seen (Gassler 
et  al. 1997). Interestingly, this data demonstrated that 
injury within the myocardium can increase blood flow 
and that a certain degree of thermal injury is required 
to induce this flow. This implies that vascular growth is 
mediated by an inflammatory response in lased regions 
of the myocardium. Furthermore, the response is specific 
to thermal-induced laser energy and/or wavelengths, as 
Fig. 4 Promotion of angiogenesis. A cross section of myocardium 
during channel creation with a TMR laser is shown and the interface 
between the inner (a) and outer (b) surface of the heart is depicted. 
The path of channel formation with the laser is depicted in c, with 
steam bubbles arising on the blood side due to heat generation 
during lasing. Clot formation and angiogenesis are shown at the site 
of the channel (d) and e as angiogenesis continues to be stimulated 
over time
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increased myocardial flow and neovascularization has 
consistently been observed in laser systems that employ 
tissue injury as compared to those that do not, such as 
sham or excimer lasers (Hughes et  al. 2000). Therefore, 
it is the inflammatory-vasculogenic mechanisms that 
are responsible for the increased vascular network that 
accompanies TMR therapy.
In vivo stand alone therapy
Individuals who have a history of multiple percutaneous 
or surgical procedures and who present with severe dif-
fuse CAD fall into the category of stand-alone therapy 
and do not meet the criteria for further PCI’s or surgi-
cal interventions. The benefits of this therapeutic option 
have shown promising results over conventional medi-
cal management treatments. A study completed in 1999 
followed 275 patients with class IV refractory angina for 
2 years (Allen et al. 1999). These patients were not eligible 
for PCIs or CABG procedures and were thus partitioned 
into a group receiving TMR therapy followed by medical 
management or medical therapy alone. Although sur-
vival estimates for both groups were similar, those that 
received TMR had an increased improvement in angina 
relief, higher freedom from cardiac events (i.e. arrhyth-
mia, myocardial infraction, or congestive heart failure), 
decreased re-hospitalizations due to cardiac events, 
increased quality of life scores and increased exercise tol-
erance stress tests (Allen et al. 1999).
The positive results found in this study prompted other 
retrospective and prospective studies to be completed. 
Collectively, these studies have examined various end-
points including operative mortality, long-term survival, 
angina relief, quality of life and exercise testing. After fol-
lowing individuals for 5 years, Allen et al. (2004) observed 
a decrease of two or more angina classes in 88  % of 
TMR patients as opposed to 44 % in medically managed 
patients (p  <  0.001). In addition, the average mortality 
rate after 1 year was determined as 8 % for TMR patients 
and 13 % for medically managed patients (p = 0.03). Con-
sequently, the observed decrease in angina relief appears 
to be sustained beyond a single year with promising mor-
tality rates in those treated with laser therapy.
Despite the convincing results found in decreased 
angina and mortality, the debate over whether TMR ther-
apy augments LV function, in particular LVEF and myo-
cardial perfusion, continues to ensue with inconsistent 
evidence. While some groups report enhanced perfusion 
and hemodynamic function (via blood flow and car-
diac output respectively) following laser therapy (Atluri 
et  al. 2008) others have disregarded this notion. Tasse 
and Arora (2007) summarized two studies where there 
were no significant differences in perfusion between 
TMR versus medical therapy groups following SPECT 
or dypiridamole-thallium stress testing. Conversely, 
they also reported an alternate study which observed 
a decrease in ischemia at 3, 6, and 12  months in TMR 
patients, compared to an increase in ischemia in patients 
receiving medical treatment alone, at the same time inter-
vals (Tasse and Arora 2007). Further comparison of LVEF 
from different studies by the same authors indicated no 
significant change after 1 year in LVEF for TMR treated 
groups as compared to controls in one study and a sig-
nificant decrease in LVEF by 3 % in another TMR group 
versus control study (Tasse and Arora 2007). Despite 
the conflicting data surrounding ventricular function, 
clear evidence supports the finding that patients receiv-
ing TMR typically require decreased drug therapy, in 
particular short acting nitrates, whereby the number of 
sublingual nitrates taken per month was reduced from 
22.1 ± 30.4 to 1.4 ± 3.9; p < 0.001 (Reyes et al. 2010; Dal-
lan et  al. 2008; Gowdak et  al. 2005). Decreased cardiac 
hospitalizations were noted at 12 months following laser 
treatment, averaging 61 % versus 31 % (p < 0.001), com-
pared to medically managed patients (Tasse and Arora 
2007).
TMR therapy as an adjunct to surgical procedures
Another option for patients with diffuse CAD is to 
undergo a CABG procedure in order to obtain partial 
revascularization, and to supplement non-vascularized 
regions with TMR. 1 year survival rates have been report-
edly higher for CABG and TMR therapies as opposed to 
CABG alone (95 versus 89 %, p = 0.05) (Allen et al. 2000). 
In addition, there have been no increased operative 
mortality rates associated with adjunctive therapy com-
pared to sole CABG treatment (1.5 versus 7.6 % respec-
tively, p = 0.02) (Allen et al. 2000) and there have been 
significant decreases reported in 30 days mortality rates 
(13 versus 28  %, p  =  0.021) (Frazier et  al. 2004). More 
importantly, studies have demonstrated that using TMR 
in combination with CABG has led to decreased repeat 
revascularizations (0 dual therapy versus 24  % CABG 
alone, p  <  0.05) (Frazier et  al. 2004) and significantly 
reduced inotropic support post-operatively (Allen et  al. 
2000). From these studies it has become evident that 
CABG plus TMR therapy is beneficial over sole CABG 
treatment since it provides increased angina relief and 
appears to reduce repeat revascularizations, as well as 
associated cardiac adverse events.
The question of whether the type of laser used is of 
importance in these procedures and whether surgi-
cal centers are choosing to include laser therapy within 
their scope of practice, has been evaluated by Tavris 
et al. (2012). They investigated 435 cardiothoracic hospi-
tals within the United States over the course of 6 years, 
examining 15,386 patients. They categorized individuals 
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into two procedure groups: those receiving TMR therapy 
alone, and those receiving TMR with CABG. They also 
subdivided these groups according to the type of laser 
(either CO2 or Ho:YAG) utilized to determine if there are 
any significant short or long term effects between laser 
devices. For TMR therapy performed in isolation or in 
combination with CABG, both lasers exhibited negligible 
long-term (>5  years) differences in morbidity and mor-
tality rates. However, short-term results indicated minor 
odds of morbidity, mortality, and operative mortality 
with the CO2 laser, owing to increased ventilation times. 
Additionally, short term results for adjunctive therapy 
reported increased incidences of acute renal failure, deep 
sternal wound infection, and operative mortality rates for 
the Ho:YAG laser, but decreased reoperation rates due to 
bleeding complications (Tavris et al. 2012).
Overall, this data demonstrates that there were 
no differences in the long-term effects between the 
two devices, however the Ho:YAG laser appeared to 
have increases in short-term consequences following 
dual therapy. It has been previously reported that the 
Ho:YAG laser introduces increased thermoacoustics 
(Fisher et  al. 1997), thermal injury (Kitade et  al. 1999) 
and tissue tearing (Genyk et  al. 2000) to the surround-
ing muscle. However, it has also been argued that despite 
increased myocardial damage, it is this damage itself that 
is paradoxically responsible for the repair and remod-
eling of ischemic myocardium. Despite these observed 
repair mechanisms, Estvold and colleagues argued that 
increased fibrosis associated with the Ho:YAG device led 
to decreased improvements in ventricular wall thicken-
ing and function compared to the CO2 laser system (Est-
vold et  al. 2010). Therefore, debate still exists over the 
extent of injury incurred by these laser devices and their 
subsequent effects on cardiac function.
Stem cell treatment with TMR therapy in an 
infarcted myocardium
The use of stem cells to treat damaged, ischemic zones 
within an infarcted myocardium has been explored 
extensively. Nascent cardiac stem cells residing in the 
myocardium are in limited supply, short lived and rely 
on immunosuppression—therefore, they can only offer 
minimal intrinsic regenerative capabilities for patients 
(Chou et  al. 2014). Even though TMR is thought to 
induce signaling via myocardial injury and inflamma-
tion, the quantity and duration of native stem cell hom-
ing has been heavily debated. The use of injected stem 
cells is thought to overcome this hurdle and aid in car-
diac repair post-myocardial infarction. Mesenchymal 
stem cell therapy as a treatment for myocardial pathol-
ogy is of particular interest due to its regenerative prop-
erties aiding in heart failure treatment. The idea that 
such stem cells or partially differentiated stem cells can 
be delivered into hearts to restore function is an appeal-
ing notion since these cells possess high yields, are multi-
potent and play a critical role in myocardial repair (Hare 
et  al. 2009; Dinsmore and Dib 2008; Chou et  al. 2014; 
Nagaya et al. 2004). They have displayed significant con-
tributions in myocardial recovery through mechanisms 
such as transdifferentiation, paracrine release, stimula-
tion of native cardiac stem cells, and inflammatory con-
trol (Chou et  al. 2014). Although the current paradigm 
for stem cell therapy focuses on their potential to differ-
entiate into cardiomyocytes and promote cardiac repair 
and regeneration (Rangappa et  al. 2003; Madonna et  al. 
2009), it has been difficult to demonstrate persistence 
and biodistribution of stem cells (Spiegelstein et al. 2007). 
Injection of these cells into the myocardium has exhib-
ited suboptimal retention rates, reportedly ranging from 
2.6 to 11.3 % (Hou et al. 2005; Dib et al. 2011). The quick 
clearance of injected stem cells has been deemed a conse-
quence of myocardial contraction, lymphatic and venous 
drainage (Richardson et al. 2013) and the hostile nature 
of an ischemic myocardium (Richardson et al. 2013; Rei-
necke et  al. 1999; Robey et  al. 2008; Abdelwahid et  al. 
2015). This limiting factor in myocardial repair is of sig-
nificance since successful cell therapy is dependent upon 
cell homing, engraftment, and survival within the scarred 
myocardial tissue (Horvath et al. 2005; Richardson et al. 
2013). The use of TMR with stem cell therapy could pro-
vide a promising solution to this problem and aid in stem 
cell homing to injured sites.
It is proposed that the inflammatory response imposed 
by lased thermal injury may be responsible for increased 
cell homing and engraftment (Shahzad et al. 2012; Patel 
et al. 2007) as well as angiogenesis (Hughes et al. 2000). 
Preliminary porcine and murine research has indicated 
that pretreatment of an infarcted myocardium with TMR 
therapy significantly enhances mesenchymal stem cell 
(MSC) engraftment (Patel et  al. 2007; Spiegelstein et  al. 
2007). This engraftment can further be heightened by 
MSC transfection with vascular endothelial growth fac-
tors (VEGF), basic fibroblast growth factors (bFGF), and 
insulin-like growth factors (70 ± 26 % survival of trans-
fected cells with TMR compared to 47 ±  18  % survival 
of non-transfected BMSC with TMR, p  <  0.05). Trans-
fected cells with laser therapy also experience an increase 
in vascular density as compared to TMR alone as early 
as 3  days following injections (Spiegelstein et  al. 2007). 
The success of growth factor mediated repair was further 
explored by the use of recombinant human basic fibro-
blastic growth factors (rhFGF-2) and adenoviral fibro-
blast growth factors-2 (AdFGF-2) with remarkable results 
in an infarcted porcine model (Horvath et al. 2005; Lutter 
et  al. 2002). Both demonstrated increased contractility 
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and angiogenesis, with an 89  % contractility improve-
ment in the AdFGF-2+TMR group compared to either 
AdFGF-2 or TMR alone, p =  0.001 via cine MRI (Hor-
vath et al. 2005). Thus, dual growth factor and laser ther-
apy may prove to be effective in candidates with ischemic 
myocardium undergoing CABG or TMR therapy.
The mechanism(s) underlying the reparative effects 
of TMR and cell therapy are still heavily debated. It 
could be that increased perfusion via channel conduits 
increases cell implantation, prior to eventual channel 
closure, thus allowing for improved engraftment and 
angiogenesis. Furthermore the release of pro-survival 
cytokines (Spiegelstein et  al. 2007) or pro-angiogenic 
growth factors such as FGF-2 (Patel et  al. 2007), from 
inflamed zones may warrant enhanced cell transplanta-
tion survival. Current findings also suggest that injection 
of MSC may mobilize endothelial progenitor cells (EPC) 
to infarcted zones, aiding in the induction of angiogen-
esis and the reparative effect noted with TMR (Shahzad 
et  al. 2012). Atluri et  al. (2008) demonstrated that sole 
TMR therapy in a porcine model was able to increase the 
amount of circulating EPCs post treatment due to the 
upregulation of NFkB (42.6  ±  27 intensity units versus 
591.6 ± 383 intensity units, p = 0.03). NFkB is a potent 
chemokine and mediator in vasculogenesis, known to 
excite various vasculogenic agents (VEGF and bFGF). It 
is thought that it may be responsible for the increase in 
EPCs within the infarcted myocardium, aiding in vas-
culogenesis and myocardial perfusion. Moreover, TMR 
therapy has been shown to upregulate angiopoitein-1 
expression (0 ±  0 intensity units vs. 241 ±  87 intensity 
units, p  =  0.003), which has been strongly associated 
with vasculogenesis and the maturation of vessels (Atluri 
et  al. 2008). Therefore, together with stem cell injec-
tion, it is quite evident that both laser and cell therapies 
can offer synergistic angiogenic effects within scarred, 
infarcted myocardium.
Clinical assessments following autologous intramyo-
cardial injection of MSC and TMR therapy have yielded 
promising results for patients with limited therapeutic 
options. Reports of decreased angina classification of at 
least two functional classes (from 3.7 ± 0.2 to 1.3 ± 0.2, 
p < 0.0001) (Dallan et al. 2008) and improved quality of 
life have been unanimous amongst all case reports (Reyes 
et al. 2010; Gowdak et al. 2008; Dallan et al. 2008; Kon-
stanty-Kalandyk et al. 2013). Evaluation of ischemic score 
and LV thickening via MRI have also demonstrated sig-
nificant improvements 6  months post treatment, with 
an average decrease in ischemic score from 1.56 ± 0.09 
to 0.93  ±  0.10 (p  =  0.01) (Gowdak et  al. 2008; Dallan 
et al. 2008; Gowdak et al. 2005). Ischemic scores, meas-
ured with MRI during pharmacological stress with dyp-
iridamole, have been used as determinants of myocardial 
perfusion, while LV thickening has been utilized as a 
predictor of contractility following therapy. Konstanty-
Kalandyk et al. (2013) further examined these parameters 
concluding that LV segments treated with bone marrow 
derived MSC  +  TMR (BMLR) have increased thicken-
ing compared to baseline (53.0  ±  7.5 vs. 45.0  ±  9.5  %; 
p = 0.06) at 1 year post-treatment (Konstanty-Kalandyk 
et  al. 2013). More importantly, they reported that in all 
but one patient, LV regions treated with BMLR did not 
demonstrate new infarctions, whereas regions left unat-
tended by BMLR revealed new or enhanced infarcted 
areas. Ejection fractions, measured pre- and post-treat-
ment, demonstrated conflicting results, concurrent 
with numerous other study findings. Although Gowdak 
et  al. reported an LVEF improvement from 27 to 43  % 
in their case report, other institutions have dismissed 
the idea that TMR and/or cell therapy has an effect on 
LVEF (Allen et al. 1999; Patel et al. 2007; Klein et al. 2004; 
Gowdak et al. 2005).
However more recent outcomes in clinical trials have 
yielded interesting results for sole stem cell therapy. In 
a meta-analysis published by Kandala et  al. (2013), the 
effect of bone-marrow derived stem cells on ischemic 
cardiomyopathy was analyzed. By examining over 519 
patients and 10 clinical trials they determined that LVEF 
increased by 4.48 % (p = 0.0001) within 6 months. Fur-
thermore they reported superior effects on LVEF with 
intramyocardial injections as opposed to intracoronary 
injections (5.13  %, p  <  0.0001 versus 2.32  %, p  =  0.3 
respectively). Other study findings included significant 
reductions in LV end-diastolic and end-systolic volumes 
within stem cell treated patients (Kandala et  al. 2013). 
These results were further supported in a larger meta-
analysis examining over 31 randomized controlled tri-
als and 1521 patients with ischemic and non-ischemic 
cardiomyopathy (Fisher et  al. 2015). Administration of 
any autologous cell therapy via any route was included 
in the study criteria. Primary endpoints revealed a sig-
nificant reduction in mortality ≥12 months with patients 
who received cell therapy alone (p  <  0.0001) as well as 
significant decreases in re-hospitalization rates among 
stem cell patients with heart failure (p = 0.002). No sig-
nificance was noted between control and treatments 
groups in regards to long-term follow-up of arrhyth-
mias (p =  0.61), however significant changes were seen 
in long-term follow-up of LVEF. Mean increase for LVEF 
was reported as 4.02 % (p = 0.007) and 3.57 % (p = 0.03) 
for ischemic heart failure patients alone. Secondary out-
comes displayed significant improvements in exercise 
tolerance (p = 0.02) and quality of life (p = 0.0003). Myo-
cardial perfusion, however, showed conflicting results. 
Four trials reported significant increases in perfusion 
while three trials found no significance. These findings 
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can suggest two points. One, that stem cell therapy alone 
may be sufficient enough to provide therapeutic effects in 
patients suffering from heart failure. It may be that there 
short-term engraftment can suffice in providing patients 
with long-term benefits. Two, that TMR may augment 
the short-comings of stem cell therapy and provide 
increased longevity of stem cell engraftment and there-
fore increased therapeutic effects. An example of this 
would include studies which report increased myocar-
dial perfusion following TMR (March 1999), and studies 
which showcase a decrease of two or more angina clas-
sifications post TMR (Leon et al. 2005).
Cost analysis
The decrease in cardiac hospitalizations associated with 
TMR has not only benefited patient outcomes but it has 
also been associated with significant hospital cost reduc-
tions. The average cost for a patient admitted for angina 
is estimated to be $3000 per visit. Clinical trials indicate 
that TMR can reduce these visits by as much as 80  %. 
Campbell et  al. (2001) analyzed 188 patients receiving 
TMR therapy or medical management at a single UK cen-
tre. The total cost for TMR therapy was quoted as $16,500 
per patient, with $3480 of that cost coming from CO2 
laser equipment use and $8630 from inpatient resource 
use. Alternatively the cost for medical management alone 
was $3720 per patient with $2900 coming from inpatient 
and outpatient episodes (Campbell et al. 2001). Although 
this paper concluded that TMR plus medical management 
is not cost effective from a UK National Health Service 
perspective, the periodical Cost Management in Cardiac 
Care (1998) argued that TMR has decreased costs of hos-
pitalization time and transfusion rates. Furthermore the 
average cost of bypass surgery is $40,000 and an angio-
plasty with a stent can amount to $20,000 with possible 
need for repetition. On the other hand TMR alone costs 
an average of $25,000 with quicker recoveries and shorter 
hospital stays as compared to complete bypass surgery. 
Although TMR may reduce expenses in the long run 
versus medical management, this cost-benefit analysis 
must be closely considered when performing adjunctive 
CABG procedures and stem cell therapies. A more recent 
multi-centre study analyzed the cost of mobilizing, har-
vesting and cryopreserving autologous blood progenitor 
cells (Mishra et  al. 2005). Although the intent of use for 
these cells was to treat malignant lymphomas and multi-
ple myeloma’s, the study highlights expenses associated 
with autologous cell delivery. The mean cost of processing 
stem cells amounted to $6544 per patient. The majority of 
this expenditure came from hospitalization, growth fac-
tors and cryopreservation. Therefore patients considering 
stem cell therapy should be aware of additional costs asso-
ciated with this treatment.
Future research
Laser therapy was first employed for use with patients 
who could not be revascularized, offering angiogenic 
properties to ischemic myocardium. Currently, this 
therapy has been extended to treat scarred, ischemic 
myocardium with the addition of cell therapy. It is this 
hybrid treatment that can offer reparative and regenera-
tive properties to injured myocardial tissue in addition to 
angiogenesis or denervation alone. Therefore, the direc-
tion of future research depends on the ability to increase 
cell homing and engraftment of these cells in order to 
allow proper repair and function of diseased hearts. Thus 
far, the literature has reported the use of MSC with laser 
therapy and their beneficial effects. Due to positive feed-
back from this dual therapy within the clinical setting it 
is now important to delineate the precise mechanisms 
responsible for the aforementioned improvements in 
cardiac function and determine whether these effects 
can sustain long-term benefits for patients. Clearly, an 
alteration in the ischemic microenvironment of the 
myocardium via laser energy is allowing for increased 
cell engraftment and survival. Therefore, the attempt to 
understand the clinical reverberations of this hybrid ther-
apy should focus on the molecular and metabolic interac-
tions occurring at the cellular level.
Conclusion
TMR has emerged as a promising therapeutic option for 
patients suffering with diffuse coronary artery disease. 
The use of TMR within this subgroup has demonstrated 
many beneficial effects, not only in the quality of life but 
also in the repair and remodeling of myocardial tissue. 
To date, this therapeutic option has exhibited encourag-
ing improvements within an ischemic heart model, with 
angiogenesis acting as the main contributor to the long-
term effects noted in patients. Considering that the aver-
age amount of tissue affected by this laser treatment is 2 g 
of muscle (using the Ho:YAG device with 40 lased chan-
nels), which corresponds to approximately 1.7–3.2  % of 
left ventricular mass (Dallan et al. 2008), it is remarkable 
how this therapy can produce significant angina relief 
and angiogenesis. The use of cell therapy in conjunction 
with TMR heightens this response and provides another 
avenue by which an ischemic myocardium can be revas-
cularized. The future of TMR therapy and research 
hinges on its collaboration with cell therapies in order 
to further enhance myocardial repair, regeneration and 
revascularization.
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